Current drug treatment and treatment patterns with antihypertensive drugs

Drugs

Volumn 52, Issue 1, 1996, Pages 1-16

  Freis, Edward D ^a,b   Papademetriou, Vasilios ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; ISRADIPINE; LABETALOL; LOSARTAN; METOPROLOL; NIFEDIPINE; PROPRANOLOL DERIVATIVE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANGINA PECTORIS; BRONCHOSPASM; CLINICAL TRIAL; COLD SENSITIVITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FLUSHING; HEADACHE; HEART BLOCK; HEART LEFT VENTRICLE MASS; HEART STIMULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; KIDNEY FUNCTION; LUNG EDEMA; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; REVIEW; SLEEP DISORDER; STROKE; SYSTOLIC HYPERTENSION; URTICARIA;

ANGINA;

EID: 0029943358     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652010-00001     Document Type: Review

References (136)

1. National Center for Health Statistics. Health promotion and disease prevention: United States, 1990. Public Health Service publication 313. Hyattsville (MD): Public Health Services. 1993
2. Excerpts from te United States Renal Data System 1993 Annual Data Report: III. Incidence and causes of treated ESRD. Am J Kidney Dis 1993; 22 Suppl. 2: 30-7
3. Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive drugs with placebo. N Engl J Med 1993; 328: 914-21
4. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706
5. Materson J, Reda DJ, Preston RA, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med 1995; 155; 1757-62
6. Freis ED, Wilson JM. Potentiating effect of chlorothiazide (Diuril) in combination with antihypertensive agents: preliminary report. Med Ann DC 1957; 9: 468
7. Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V) [editorial]. Arch Intern Med 1993; 153: 154-83
8. Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation 1959; 20: 1028-36
9. Frohlich ED, Schnaper HW, Wilson IM, et al. Hemodynamic alterations in hypertensive patients due to chlorothiazide. N Eng J Med 1960; 262: 1261-3
10. Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95: 611-18
11. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995; 122: 223-6
12. Kassirer JP, Harrington JT. Diuretics and potassium metabolism; a reassessment of the need, effectiveness and safety of potassium therapy. Kidney Int 1977; 11: 505-15
13. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38
14. Wilhelmsen I, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72
15. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104
16. IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker osprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-92
17. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64
19. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54
20. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1992; 338: 1281-5
21. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-7
22. Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. London: Churchill Livingstone, 1988
23. Fitzgerald JD, Ruffin R, Smedstad R, et al. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 1978; 13: 81-9
24. McDevitt DG, Brown HC, Carruthers SG. Influence of intrinsic sympathermimetic activity and cardio-selectivity on beta-adrenoceptor blockade. Clin Pharmacol Ther 1977; 21: 356-66
25. Lund-Johansen P. The pharmacology of combined α- and β-blockers II: hemodynamic effects of labetolol. Drugs 1984; 28 Suppl. 2: 35-50
26. Man in 't Veld AJ, van den Meiracker AH. Effects of antihypertensive drugs on cardiovascular hemodynamics. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 2753-63
27. 1-selective blocking agents? J Hypertens 1985: 3 Suppl. 3: S243-45
28. Douglas-Jones AP, Cruickshank JM. Once-daily dosing with atenolol in patients with mild to moderate hypertension. BMJ 1977; 1: 990-1
29. Murphy MB, Scriven AJL, Dollery CT. Role of nifedipine in the treatment of hypertension. BMJ 1983; 287: 257-9
30. Buhler FR. Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension 1983; 5 (5 Pt 2): III94-100
31. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Clin Pharmacol Ther 1990; 46: 163-97
32. Kendall MJ, Lynch KP, Hjalmarson A, et al. β-Blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-67
33. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974; 291: 389-401
34. Atlas SA, Case DB, Sealsy JE, et al. Interruption of the reninangiotensin system in hypertensive patients by captopril-induced sustained reduction in aldosterone secretion, potassium retension and natriuresis. Hypertension 1979; 1: 274-80
35. Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Physiol 1977; 233: F169-184
36. Zimmerman BG, Sybart EG, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2: 581-8
37. Bonner G, editor. Pharmacological and clinical aspects of the kallikrein-kinin system. Basel: Birkhauser, 1992
38. Geisterfer AAT, Peach MG, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia in cultural aortic smooth muscle cells. Circulation Res 1988; 62: 749-56
39. Muiesan G, Alicandri CL, Agabiti-Rosce E, et al. Angiotensin-converting enzyme inhibition, catecholomines and hemodynamics in essential hypertension in normotensive and hypertensive man. Clin Exp Hypertens 1982; A4: 761-89
40. Malini PL, Strocchi E, Vatiancoli G, et al. Inhibition and pressure responsiveness to norepinephrine in hypertensive patients. J Clin Pharmacol 1990; 30: 422-4
41. Cody RJ, Bravo EL, Fouad FM, et al. Cardiovascular reflexes during long-term converting enzyme inhibition and sodium depletion. Am J Med 1981; 71: 422-6
42. Heel RC, Brogden RN, Speight TM, et al. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 20: 409-52
43. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide/captopril and the combination in black and while mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: 52-5
44. Cooper WD, Glover DR, Kimber GR. Influence of age on blood pressure response to enalapril. Gerontology 1987; 33 Suppl. 1: 48-54
45. Foult JM, Travolaro O, Antony J, et al. Direct myocardial and coronary effects of enalapril in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation 1988; 77: 337-44
46. Mettauer B, Rouleau JL, Daly P. The effect of captopril in hypertensive patients with stable angina. Postgrad Med J 1986; 2 Suppl.: 54-8
47. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity after myocardial infarction: results of the Survival and Ventricular Enlargement Study. N Engl J Med 1992; 327: 669-77
48. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
49. Koher L, Torp-Pedersen C, Carlson JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6
50. Deedwania PC. Angiotensin converting enzyme inhibitors in congestive heart failure. Arch Intern Med 1990; 150: 1798-805
51. Mulvaney MJ. Is there a role for the vascular renin-angiotensin system in the determination of vascular structure? Blood Vessels 1991; 28: 224-30
52. Parving HH, Jensen HB, Mogensen CE, et al. Increased urinary albumin excretion in benign essential hypertension. Lancet 1974; 1: 231-7
53. Kannel WH, Stampfer MJ, Castelli WP. The prognostic significance of proteinuria: the Framingham Study. Am Heart J 1984; 108: 1347-52
54. Bianchi S, Bigazzi R, Balderi G, et al. Microalbuminuria in patients with essential hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 1991; 4: 291-6
55. Bauer JH, Ream C, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 1987; 147: 1397-400
56. Mann JFE, Reisch C, Cicerello E, et al. Use of angiotensin enzyme converting inhibitors for the preservation of kidney function: a retrospective study. Nephron 1990; 55: 38-42
57. Bjoreck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with nephropathy. BMJ 1996; 293: 411-4
58. Smith RD, Franklin SS. Comparison of effects of enalapril plus hydrochlorothiazide versus triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79 Suppl. 3C: 14-23
59. Kricik DE, Browning PJ, Kopelman RI, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a single kidney. N Engl J Med 1983; 308: 373-6
60. Lewis HL, Hunsicker LG, Pain RP, et al. The effect of converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
61. Matthews DM, Walhen CG, Bell D, et al. The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics. Postgrad Med J 1986; 62 Suppl. 5: 73-5
62. Gauch KW, Guenther B, Hart W, et al. Improvement of impaired postoperative insulin action by bradykinin. Biol Chem Hoppe Seyler 1991; 367: 207-10
63. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144: 1947-53
64. Freis ED, Materson BL. Captopril in mild to moderate hypertension: effect of low doses and of added diuretic. Prog Pharmacol 1984; 5: 87-92
65. Materson BJ, Reda WC, Cushman WC. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens 1995; 9: 791-96
66. Weinberger MH. Influence of an angiotensin converting enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5 Suppl. III: 132-38
67. Crogg SH, Lemine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-64
68. Sebastian JL, McKinney WP, Kaufman J, et al. Angiotensin-converting enzyme inhibitors and cough: prevalence in an outpatient clinic population. Chest 1991; 99: 36-9
69. Pister Bm, Timmermans PC, Wong AJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-1
70. Brunier M, Rutschman B, Nussbarger J, et al. Renal effects of the angiotensin II antagonist losartan in volunteers on a low and high sodium diet. Circulation 1992; 86: 1-545
71. Brunner HR, Christen Y. Clinical experience with angiotensin II receptor antagonists. Am J Hypertens 1992; 5: 2438-45
72. Nelson E, Merrill D. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist in essential hypertension. J Hypertens 1991; 9: S468-9
73. Weber M. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992; 5: 2458-518
74. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-7
75. Nakashima M, Uemutsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-5
76. Hulthen UL, Bolli P, Amann FW, et al. Enhanced vasidilatation in essential hypertension by calcium channel blockade with verapamil. Hypertension 1982; 4 Suppl. II: 26-31
77. Katy AM, Hager WD, Messineo FC, et al. Cellular actions and pharmacology of the calcium channel blocking drugs. Am J Med 1984; 77 Suppl. 2B; 2-10
78. Leonetti G, Cuspidi C, Sampieri L, et al. Comparison of cardiovascular, renal and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1982; 4 Suppl. 3: S319-24
79. Thananoparvan C, Golub MS, Eggena P, et al. Renal effects of nitrendipine monotherapy in essential hypertension. J Cardiovasc Pharmacol 1985; 6 Suppl. 7: S1040-4
80. Nicholson JP, Resnick LM, Laragh JH. The antihypertensive effect of verapamil at extremes of dietary sodium intake. Ann Intern Med 1987; 107: 329-34
81. Cappuccio FP, Markandu ND, MacGregor GA. Calcium antagonists and sodium balance: effect of changes in sodium intake and of the addition of a thiazide diuretic on the blood pressure lowering effect of nifedine. J Cardiovasc Pharmacol 1987; 10 Suppl. 10: S557-60
82. Buhler FR, Hulthen UL, Kiowski W, et al. Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients. Clin Sci 1982; 63: 439-42
83. Weinberger MH. The role of age, race and plasma renin activity in influencing the blood pressure response to nitrendipine or hydrochlorothiazide. J Cardiovasc Pharmacol 1987; 9 Suppl. 4: 272-5.
84. Brouwer RML, Bolli P, Erne P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol 1985; 7 Suppl. 4: S88-91
85. Davies J, Jensen H, Gardsal P. A double-blind comparison of amlodipine and placebo added to open enalapril in patients with moderate to severe essential hypertension. J Cardiovasc Pharmacol 1991; 17 Suppl. 1: S16-18
86. Brouwer RM, Follath F, Buhler FR. Review of the cardiovascular adversity of the calcium antagonist beta blocker combination: implications for antihypertensive therapy. J Cardiovasc Pharmacol 1985; 7 Suppl. 4: S38-44
87. Belg GG, Doering W, Mundes R, et al. Effect of various calcium antagonists on blood level and renal clearance of digoxin. Circulation 1981; 64 Suppl. IV: IV-24
88. Farringer JA, Green JA, O'Rourke RA, et al. Nifedipine-induced alterations in serum quinidine concentratons. Am Heart J 1985; 108: 1570-2
89. Smith MS, Benyunes MC, Bjornsson TD, et al. Influence of cimetidine on verapamil kinetics and dynamics. J Clin Pharmacol Ther 1984; 36: 551-5
90. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction. Lancet 1986; 1: 979
91. Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J 1985; 109: 163-4
92. Henry PO. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980; 46: 1047-58
93. Krebs R. Adverse reactions with calcium-antagonists. Hypertension 1983: 5 (4 Pt 2): 11125-9
94. Rojdmark S, Anderson DEH, Hed R, et al. Effect of verapamil on glucose response to intravenous injection of glucagon and insulin in healthy subjects. Horm Metab Res 1980; 12: 285-90
95. Held Ph, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-92
96. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-97
97. Holland Interuniversity Nifedipine/Metropolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double-blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metroprolol or both. Br Heart J 1986; 56: 400-13
98. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-61
99. Danish Study Group on Verapamil in Myocardial Infarction. Effect of varapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial (II-DAVIT II). Am J Cardiol 1990; 66: 77-85
100. Multicentre Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92
101. Psaty BM, Heckbert S, Koepsel T, et al. The risk of myocardial infarction associated with antihypertensive drug therapy. JAMA 1995; 274: 620-25
102. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma 1994; 932; 4
103. Ferguson JJ, Monomura S. Highlights from the 58th Annual Scientific Meeting of the Japanese Circulation Society. Circulation 1994; 90: 2194-95
104. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier [editorial]. Circulation 1995; 92: 1068-73
105. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92: 1074-8
106. Liebson PR, Savage DD. Echocardiography in hypertension: a review. II: echocardiographic studies of the effects of antihypertensive agents on left ventricular wall mass and function. Echocardiography 1987; 4: 215-49
107. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
108. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52
109. Liebson PR. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990; 3: 512-7
110. Trimarco B, Wikstrand J. Regression of cardiovascular structural changes by antihypertensive treatment: functional consequences and time course of reversal as judged from clinical studies. Hypertension 1984; 6 Suppl. 3: 150-7
111. Sen S. Regression of cardiac hypertrophy: experimental animal model. Am J Med 1983; 75 Suppl. 3A: 87-93
112. Fouad-Tarazi F, Liebson PR. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension. Hypertension 1987; 4 Suppl. 2: 65-8
113. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertension patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
114. Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24: 1492-8
115. Pfeffer MA, Pfeffer JM. Pharmacologic regression of cardiac hypertrophy in experimental hypertension. J Cardiovasc Pharmacol 1984; 6 Suppl. 6: 865-9
116. Drayer JIM, Gardin MJ, Weber MA, et al. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 1982; 32: 283-88
117. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992; 13 Suppl. G: 28-33
118. Moser M, Setaro JF. Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics. Eur Heart J 1991; 12: 1034-9
119. Reichek N, Franklin BB, Chandler T, et al. Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J 1982; 3: 165-9
120. Gottdiener J, Reda D, Notargiacomo A, et al. Comparison of monotherapy effects on LV mass regression in mild-to-moderate hypertension: differences between short and long term therapy [abstract]. J Am Coll Cardiol 1992; 19: 85A
121. Gottdiener JS, Papademetriou V, Meyer PS, et al. Isradipine vs hydrochlorothiazide for reduction of LV mass: results of a multicenter trial [abstract]. Circulation 1995; 92 Suppl. 1: 1-803
122. Fagerberg B, Berglund A, Andersson OK, et al. Cardiovascular effects of weight reduction versus antihypertensive drug treatment: a comparative, randomized, 1-year study of obese men with mild hypertension. J Hypertens 1991; 5: 431-9
123. MacMahon SW, Wilcken DEL, MacDonald GJ. The effect of weight reduction on left ventricular mass. N Engl J Med 1986; 6: 314-34
124. Ferrara L, DeSimone G, Pasanisi F, et al. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 1984; 6: 755-9
125. Jula A, Karanko H. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation 1994; 89: 1023-31
126. Schulman SP, Weiss JL, Beeker LC. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990; 322: 1350-6
127. Khatri IM, Gottdiener JS, Notargiacomo AV, et al. The effect of therapy on left ventricular function in hypertension. Clin Sci 1980; 54: 435s-9s
128. Oren S, Messerli FH, Grossman E. et al. Immediate and short-term cardiovascular effects of lisinopril, a new angiotensin-converting enzyme inhihitor, in patients with essential hypertension. J Am Coll Cardiol 1991; 17: 1183-7
129. Aurigemma G, Gottdiener J, Gaasch W, et al. Effect of 6 antihypertensive drugs on HCG left ventricular hypertrophy [abstract no. 933-100]. J Am Coll Cardiol 1995 Feb; Special Issue: 122A
130. Muiesan ML, Agabiti-Rosei E, Romanelli G. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal, and redevelopment of hypertension. J Cardiovasc Pharmacol 1991; 17 Suppl. 2: 179-81
131. Koren MJ, Ulin RJ, Laragh JH, et al. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis [abstract). Am J Hypertens 1991; 4: 1A
132. Sagie A, Larson SD, Levy D. The natural history of borderline hypertension. N Engl J Med 1993; 329: 1912-7
133. Vakonas PS, Kannel WB, Cupples LA. The epidemiology and risk of hypertension in the elderly: the Framingham Study. J Hypertens 1988; 6 Suppl.: 53-9
134. Curb JD, Barhone NO, Entwistle G, et al. Isolated systolic hypertension in 14 communities. Am J Epidemiol 1985; 3: 362-70
135. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult populations: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
136. Caldwell JR, Cobb S, Dowling MD, et al. The dropout problems in antihypertensive treatment. J Chron Dis 1970; 22: 579-92